1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Veracyte, Inc.

Veracyte, Inc.

VCYT
Veracyte, Inc.US flagNASDAQ
57.26
USD
-1.87
- -
4.57BMarket Cap

Total Valuation

Veracyte, Inc. carries a market capitalization of 4.57B, placing it among publicly traded companies globally. Its enterprise value stands at 2.14B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap4.57B
Enterprise Value2.14B

Share Statistics

Veracyte, Inc. currently has 79.79M shares outstanding.

Shares Outstanding79.79M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Veracyte, Inc. trades at a trailing price-to-earnings ratio of 28.90. The price-to-sales ratio is 4.69, and the price-to-book ratio stands at -7.29.

PE Ratio28.90
PS Ratio4.69
PB Ratio-7.29
P/TBV Ratio5.18
P/FCF Ratio14.60
P/OCF Ratio15.31

Enterprise Valuation

On an enterprise value basis, Veracyte, Inc. trades at an EV/EBITDA multiple of 17.65 and an EV/FCF ratio of 12.11. The EV/Sales ratio of 3.96 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 21.44 provides insight into valuation relative to core operating earnings.

EV / Sales3.96
EV / EBITDA17.65
EV / EBIT21.44
EV / FCF12.11

Financial Position

Veracyte, Inc. maintains a current ratio of 9.31, meaning it holds 9.3x the short-term assets needed to cover near-term liabilities.

Current Ratio9.31
Quick Ratio8.72
Debt / Equity2.93
Debt / EBITDA0.32
Interest CoverageN/A

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)6.40
Return on Invested Capital (ROIC)7.38
Return on Capital Employed (ROCE)-25.30
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover6.90

Taxes

Over the trailing twelve months, Veracyte, Inc. has paid 2.73M in income taxes, reflecting an effective tax rate of 3.01.

Income Tax2.73M
Effective Tax Rate3.01

Stock Price Statistics

Veracyte, Inc.'s stock has gained approximately 148.63222% over the past 52 weeks. The 50-day moving average sits at 50.08, while the 200-day moving average is 40.84.

Beta (5Y)N/A
52-Week Price Change148.63222%
50-Day Moving Average50.08
200-Day Moving Average40.84
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Veracyte, Inc. generated 541.74M in revenue and converted that into 88.01M in net income, yielding earnings per share of 1.10. EBITDA reached 121.46M, while operating income came in at 99.98M.

Revenue541.74M
Gross Profit384.18M
Operating Income99.98M
Pretax Income90.75M
Net Income88.01M
EBITDA121.46M
EBIT99.98M
Earnings Per Share (EPS)1.10

Balance Sheet

Veracyte, Inc. holds 439.06M in cash and equivalents against 39.33M in total debt, resulting in a net debt position of -263.14M. Total book value stands at -348.84M, with working capital of 466.06M providing operational flexibility.

Cash & Cash Equivalents439.06M
Total Debt39.33M
Net Debt-263.14M
Equity (Book Value)-348.84M
Book Value Per Share-4.42
Working Capital466.06M

Cash Flow

Veracyte, Inc. produced 166.16M in operating cash flow over the past twelve months. After subtracting -10.82M in capital expenditures, free cash flow totaled 155.34M - equivalent to 1.97 per share.

Operating Cash Flow166.16M
Capital Expenditures-10.82M
Free Cash Flow155.34M
FCF Per Share1.97

Margins

Veracyte, Inc. operates with a gross margin of 70.92, reflecting its pricing power and cost economics. The operating margin of 18.45 and net profit margin of 16.25 provide insight into operational efficiency.

Gross Margin70.92
Operating Margin18.45
Pretax Margin16.75
Profit Margin16.25
EBITDA Margin22.42

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield0.17
FCF Yield6.85

Scores

Veracyte, Inc. posts an Altman Z-Score of 18.20, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score18.20